Out with the Old, in with the ... Newish?

  It takes a strong leader to admit when his time is up. Endologix CEO John McDermott is that type of leader, which he proved this week with the announcement that he will be stepping down as CEO of the struggling endovascular aneurysm repair (EVAR) company.     Endologix has had its fair share of hurdles over the past couple of years, but it seems like things might finally be looking up for the Irvine, CA-based company. In May, the company promoted John Onopchenko to the role of CEO. Prior to the promotion, Onopchenko was the company's chief operating officer, a position he took in October 2017. "At that time, the company had recently experienced the AFX2 recall and a temporary suspension of our CE mark,"  Onopchenko told investors during the company's first-quarter earnings call in May, the same day he his promotion was announced. "That reality drove my focus over the last six months and led me to take a critical look into our quality systems, including how we design and develop products, our production and quality management review processes, along with our supplier management practices. The team has embraced my continuous improvement mandate, and I’m proud to say that we are upping our game on all fronts." Endologix just took a big step forward on what has been a long and winding road to FDA approval of its Nellix endovascular aneurysm sealing (EVAS) system. The Irvine, CA-based company said the first patient was treated in its EVAS2 confirmatory clinical st...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news